Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
about
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expressionPhase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancerImpacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancerClinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer.Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer.Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodentsTherapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysisA predictive factor for the response to S-1 plus cisplatin in gastric cancer.Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect.Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancerNew challenges and inspired answers for anticancer drug discovery and developmentCombination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis.Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: Phase II Study of S-1, S-1 plus CisPhase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patientsPhase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.Effects of a concurrent chemoradiotherapy with S-1 for locally advanced oral cancer.Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens.Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer.Development and validation of a HPLC-MS/MS method with electrospray ionization for quantitation of potassium oxonate in human plasma: Application to a pharmacokinetic study.A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer.A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupPrognostic significance of dihydropyrimidine dehydrogenase expression in breast cancerPhase II study of S-1 in patients with advanced biliary tract cancer.Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.The role of S-1 in the treatment of gastric cancer.Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic modelLong-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer.S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial.
P2860
Q26747641-4F5B579B-8998-467A-BDA4-C14889B8CE72Q28361226-C7E187C0-E083-4091-A379-A842CC1259BAQ33317139-B069552D-53ED-471D-A47A-10DA5C704422Q33366682-09CE2914-5E6E-411B-BB12-16BFC744E443Q33371306-92F857D1-7F50-4E17-A2BD-E31915A414CAQ33390208-D96B5E14-06E4-4EAA-962D-C45FB9DC1E57Q33398040-74403C3E-7115-4B05-A549-2D72D1E7C3B5Q33403227-F1347208-24E6-49EC-9BD5-494D5470D3C5Q33424985-D99F0DBA-CE02-4353-B5EC-BA73AE051DE3Q33442997-44E5859A-646B-4483-BAF8-FE3EEEB271B6Q33884698-34D2EEBA-AB92-47C3-9DA8-706858130273Q33912151-282D6C89-45F3-4217-BA01-A90C77F45FCCQ34155072-127D6A87-9573-41DA-8E3C-04BF48F6D1C5Q34372789-519DDF7B-C2A1-4B3A-BB96-34AE321A898EQ34733346-31439FA2-28BD-4ADC-B318-A99F62BDFF7AQ34981175-A3D45F8B-694B-4528-9AC2-38571D4B8959Q35180039-EDF2A7D4-C45C-4C2C-AF2E-52D6D438BF7DQ35181033-CE6F12CF-D1DD-413A-8E2C-881C52346DB8Q35482173-617B8FEE-17E2-4138-99A2-55A158660D16Q35754239-0951018B-D32E-4B9A-A4FE-1A7B3BF295D6Q35756882-B3F51325-754C-45A0-89DE-82BFDB786990Q35775244-27AFADF8-CDFC-4AFC-8FF4-69F38D206EE6Q36126517-C1CEFA42-54DD-4829-A6BE-6C59136BC861Q36217041-3766051D-9643-4E42-A9C0-B4E2D99391CBQ36403318-CDC6195C-8EBE-43E6-AECB-465AF5695175Q36603976-E5E859DB-627A-4766-A3A2-617BE86FCBBDQ36609407-D369B9A7-990C-4FD8-BB3D-95F64CD4B010Q36611381-01D1DE1C-0F8A-42A2-A063-79B824B39D40Q36612624-CF992541-76E5-44A2-8F49-D8175E9E79BEQ36615451-9B7AADBA-FA2D-4AFC-B83A-F41AAB028BDAQ36615597-84BBBF34-BD4C-4122-A2E3-3A28F44B87E5Q36621749-5302F3D8-7E78-49F7-B40E-390090993B2FQ36643694-97C0EBDE-00BB-4A39-9F13-9DF117044768Q36696249-49C6E47B-58CA-426A-B250-5CC652F03B07Q36795339-6474BCDA-4556-4991-97A9-E83DA36623EDQ36999930-A2BE008D-EB82-43F1-B0FB-5E6F7A11794DQ37117556-47AC9F0C-B052-4579-BC45-A0E25031BDC4Q37170729-EBC0D409-77C4-4FA9-8EC0-D0C52490DC58Q37252364-B3D977C0-1A9E-4061-B7EB-C7E2AE5B4A4FQ37256849-A67FC90A-4A36-4BAF-B860-07B7085C7653
P2860
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Antitumor activity of 1 M tega ...... ally implanted into nude rats.
@en
type
label
Antitumor activity of 1 M tega ...... ally implanted into nude rats.
@en
prefLabel
Antitumor activity of 1 M tega ...... ally implanted into nude rats.
@en
P2093
P1433
P1476
Antitumor activity of 1 M tega ...... ally implanted into nude rats.
@en
P2093
Fukushima M
Shirasaka T
P304
P407
P577
1996-06-01T00:00:00Z